Modality
Bispecific Ab
MOA
FGFRi
Target
GPRC5D
Pathway
Autophagy
RA
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
~Jun 2017
→ ~Sep 2018
Phase 3
~Dec 2018
→ ~Mar 2020
NDA/BLA
Jun 2020
→ Aug 2026
NDA/BLACurrent
NCT07532839
2,547 pts·RA
2021-05→2026-08·Active
NCT04390910
2,250 pts·RA
2020-06→TBD·Recruiting
4,797 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-265mo awayPh3 Readout· RA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-08-26 · 5mo away
RA
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 |